Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting
04 Dezembro 2023 - 6:01PM
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage
biopharmaceutical company developing targeted protein modulation
drugs designed to treat patients with hematologic malignancies and
solid tumors, today announced that it will host a live webcast to
review clinical data from the Phase 1 clinical trials of its
Bruton’s tyrosine kinase (BTK) degrader programs, NX-5945 and
NX-2127, which are being evaluated in patients with relapsed or
refractory B cell malignancies, at 8:30 p.m. PST (11:30 p.m. EST)
on Monday, December 11, 2023.
The webcast will feature a presentation by guest speaker Alexey
Danilov, M.D., Ph.D., professor, Department of Hematology and
Hematopoietic Cell Transplantion, and associate director of the
Toni Stephenson Lymphoma Center, City of Hope National Medical
Center, who will provide a clinical update on the Phase 1 trial of
NX-2127 for which he is a principal investigator. Paula G.
O’Connor, M.D., Nurix’s senior vice president of clinical
development, will provide a clinical update from Nurix’s ongoing
Phase 1 trial of NX-5948.
Webcast detailsThe live webcast event, which
will begin at 8:30 p.m. PST (11:30 p.m. ET) on Monday, December 11,
2023, and the subsequent replay, will be available in the Investors
section of the Nurix website under Events and Presentations.
About NX-5948NX-5948 is an investigational,
orally bioavailable, small molecule degrader of BTK. NX-5948 is
currently being evaluated in a Phase 1 clinical trial in patients
with relapsed or refractory B cell malignancies. Additional
information on the ongoing clinical trial can be accessed at
clinicaltrials.gov (NCT05131022).
About NX-2127NX-2127 is a novel bifunctional
molecule that degrades BTK and cereblon neosubstrates Ikaros
(IKZF1) and Aiolos (IKZF3). NX-2127 is currently being evaluated in
a Phase 1 clinical trial in patients with relapsed or refractory B
cell malignancies. Additional information on the ongoing clinical
trial can be accessed at www.clinicaltrials.gov (NCT04830137).
About Nurix Therapeutics, Inc.Nurix
Therapeutics is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of innovative
medicines based on the modulation of cellular protein levels as a
novel treatment approach for cancer and other challenging diseases.
Leveraging extensive expertise in E3 ligases together with
proprietary DNA-encoded libraries, Nurix has built DELigase, an
integrated discovery platform, to identify and advance novel drug
candidates targeting E3 ligases, a broad class of enzymes that can
modulate proteins within the cell. Nurix’s drug discovery approach
is to either harness or inhibit the natural function of E3 ligases
within the ubiquitin-proteasome system to selectively decrease or
increase cellular protein levels. Nurix’s wholly owned, clinical
stage pipeline includes targeted protein degraders of Bruton’s
tyrosine kinase, a B-cell signaling protein, and inhibitors of
Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that
regulates activation of multiple immune cell types including T cell
and NK cells. Nurix is headquartered in San Francisco, California.
For additional information visit http://www.nurixtx.com.
Forward-Looking Statements
This press release contains statements that relate to future
events and expectations and as such constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. When or if used in this press release, the
words “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,”
and similar expressions and their variants, as they relate to
Nurix, may identify forward-looking statements. All statements that
reflect Nurix’s expectations, assumptions or projections about the
future, other than statements of historical fact, are
forward-looking statements, including, without limitation,
statements regarding the planned timing for the provision of
updates and findings from Nurix’s clinical trials. Forward-looking
statements reflect Nurix’s current beliefs, expectations, and
assumptions regarding the future of Nurix’s business, its future
plans and strategies, its preclinical and clinical results, future
conditions and other factors Nurix believes are appropriate in the
circumstances. Although Nurix believes the expectations and
assumptions reflected in such forward-looking statements are
reasonable, Nurix can give no assurance that they will prove to be
correct. Forward-looking statements are not guarantees of future
performance and are subject to risks, uncertainties and changes in
circumstances that are difficult to predict, which could cause
Nurix’s actual activities and results to differ materially from
those expressed in any forward-looking statement. Such risks and
uncertainties include, but are not limited to: (i) the timing and
results of Nurix’s preclinical studies and clinical trials; (ii)
Nurix’s ability to fund development activities and achieve
development goals; (iii) the impact of macroeconomic conditions and
global events on Nurix’s business, clinical trials and financial
condition; and (v) other risks and uncertainties described under
the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q
for the fiscal quarter ended August 31, 2023, and other SEC
filings. Accordingly, readers are cautioned not to place undue
reliance on these forward-looking statements. The statements in
this press release speak only as of the date of this press release,
even if subsequently made available by Nurix on its website or
otherwise. Nurix disclaims any intention or obligation to update
publicly any forward-looking statements, whether in response to new
information, future events, or otherwise, except as required by
applicable law.
Contacts:
InvestorsSilinda NeouNurix
Therapeuticsir@nurixtx.com
Elizabeth Wolffe, Ph.D.Wheelhouse Life Science
Advisorslwolffe@wheelhouselsa.com
MediaAljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Nurix Therapeutics (NASDAQ:NRIX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Nurix Therapeutics (NASDAQ:NRIX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024